Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-6.49 Insider Own2.30% Shs Outstand340.85M Perf Week0.06%
Market Cap5.27B Forward P/E2.93 EPS next Y5.27 Insider Trans2.75% Shs Float332.43M Perf Month-3.92%
Income-2256.30M PEG- EPS next Q1.22 Inst Own66.80% Short Float9.82% Perf Quarter-45.98%
Sales10.01B P/S0.53 EPS this Y-133.00% Inst Trans20.71% Short Ratio1.81 Perf Half Y-34.99%
Book/sh11.92 P/B1.30 EPS next Y-3.11% ROA-4.70% Target Price24.66 Perf Year-84.09%
Cash/sh1.93 P/C8.00 EPS next 5Y11.07% ROE-42.90% 52W Range13.77 - 119.87 Perf YTD-84.79%
Dividend- P/FCF13.57 EPS past 5Y4.40% ROI3.70% 52W High-87.10% Beta-0.13
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin73.80% 52W Low12.27% ATR1.24
Employees22000 Current Ratio1.50 Sales Q/Q-11.00% Oper. Margin-5.20% RSI (14)37.38 Volatility4.03% 5.81%
OptionableYes Debt/Eq7.31 EPS Q/Q- Profit Margin-22.50% Rel Volume0.51 Prev Close15.44
ShortableYes LT Debt/Eq7.29 EarningsNov 08 BMO Payout- Avg Volume18.02M Price15.46
Recom3.00 SMA20-8.29% SMA50-21.88% SMA200-44.53% Volume9,219,329 Change0.13%
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Jun-08-16Reiterated RBC Capital Mkts Sector Perform $58 → $33
Jun-08-16Reiterated Mizuho Underperform $18 → $11
May-03-16Reiterated Rodman & Renshaw Buy $105 → $102
Apr-12-16Reiterated RBC Capital Mkts Sector Perform $69 → $65
Apr-11-16Reiterated Rodman & Renshaw Buy $118 → $105
Dec-09-16 02:40PM  Bill Ackman Comments on Valeant Pharmaceuticals International
08:00AM  Why These Billionaire Steve Cohen Picks Deserve Your Attention at Insider Monkey
Dec-08-16 05:40PM  Express Scripts Responds To Citron: 'We're Nothing Like Philidor'
04:19PM  5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices
11:55AM  Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 PR Newswire
11:55AM  Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 CNW Group
11:52AM  Bill Ackman Releases Pershing Square 3rd-Quarter Letter
10:16AM  Bill Ackman's Pershing Square Q3 Shareholder Letter Weighs In On Valeant, Chipotle
10:08AM  Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK
08:47AM  Amid Horrendous Year, Crispin Odey Turns to These Stocks for Reprieve at Insider Monkey
01:00AM  Pharming Announces Completion of Acquisition of All North American Commercialisation Rights for RUCONEST® From Valeant PR Newswire
Dec-07-16 07:01PM  Cramer: Make a Deal or Face the Wheel
12:39PM  Is The Valspar Corp (VAL) A Good Stock To Buy? at Insider Monkey
11:49AM  Why Valeant Pharmaceuticals (VRX) Could Be Positioned for a Slump
09:33AM  Why Progenics Pharmaceuticals, Inc. Stock Climbed 76.5% in November at Motley Fool
09:26AM  3 Toxic Value Stocks to Avoid in 2017 at Motley Fool
09:14AM  Trump: I'm Going To Bring Down Drug Prices
Dec-06-16 02:49PM  Surprise! The SEC Isn't Happy With Valeant Pharmaceuticals Again at Motley Fool
Dec-05-16 12:48PM  3 Prime Reasons Valeant Pharmaceuticals Intl. Inc. Shares Dove 11% in November at Motley Fool
12:25PM  Can Donald Trump Make Valeant Stock Great Again? (VRX, XLV) at Investopedia
Dec-04-16 05:12PM  Is Valeant Pharmaceuticals Intl Inc (VRX) A Good Stock To Buy? at Insider Monkey
06:49AM  Is Mylan Being Really Smart -- Or Really Arrogant? at Motley Fool
Dec-02-16 06:06PM  [$$] Week in Review, December 2 at Financial Times
11:04AM  Analysts Are Bullish on Valeant
11:00AM  Bill Ackmans Biggest Q3 Moves As He Seeks Elusive Turnaround at Insider Monkey
10:07AM  Ackman Scores Big November on Fannie, Freddie Gains at The Wall Street Journal
10:04AM  Is Valeant Exposed to Default Risk?
08:04AM  Yes, There Will Be Margin Erosion for Valeant in 2017
Dec-01-16 11:04AM  Whats Forcing Valeant to Sell Its Core Assets?
10:47AM  3 Drug Stocks Investors Shouldn't Touch With a 10-Foot Pole in 2017 at Motley Fool
10:05AM  How Does Valeant Plan to Resume Growth beyond 2016?
08:11AM  Chou Associates REALLY Loves Its Portfolio, Because It Didnt Touch It Last Quarter at Insider Monkey
08:05AM  Why Wasnt Valeants Enormous Growth Sustainable?
08:02AM  Ranking the Activists for Proxy Season 2016
07:06AM  Valeant Stock Plunges 11% on Failed Salix Sale (VRX) at Investopedia
06:49AM  Is Computer Sciences Corporation (CSC) A Good Stock To Buy? at Insider Monkey
Nov-30-16 06:47PM  SEC Discloses Correspondence Over Valeant's Accounting Practices -7.98%
05:41PM  SEC Again Criticizes Valeant Over Non-GAAP Financial Measures at The Wall Street Journal
05:04PM  Why Valeant Pharmaceuticals, Costamare, and First Bancorp Slumped Today at Motley Fool
05:03PM  Valeant-Takeda Salix Negotiations Bust On $10 Billion Price: Report
04:49PM  Valeant slumps 8% after talks to sell stomach-drug unit fall apart at CNBC
04:10PM  Valeant, Salix, Sales Force and Asset Sales
03:04PM  When Will Valeant Resume Its Top Line Growth?
02:50PM  Valeant: First No Salix Sale, Now the SEC Sees Accounting Issues?!?! at Barrons.com
02:44PM  Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls
01:04PM  What Does Valeants Institutional Ownership Look Like?
01:04PM  How to Trade Wednesday's Most Active Stocks -- Chesapeake Energy, American Eagle, More
12:40PM  Valeant and Tribune Media Rebounds Not in Sight
12:34PM  Takeda's talks to acquire Valeant's Salix stall-sources
12:21PM  [$$] Valeant's talks to sell Salix unit for $10bn break down at Financial Times
11:54AM  Valeant Said to Plan to Keep Salix After Takeda Deal Falls Apart
11:54AM  Valeant Said to Keep Salix After Takeda Deal Falls Apart at Bloomberg
11:49AM  Why Valeant is Crumbling at Barrons.com
11:04AM  Has Valeant Really Bottomed Out?
10:58AM  Valeant Plummets on Reports of Salix Takeover Breakdown
10:34AM  Valeant Drops After Report Salix Sale Discussions Broke Down
10:18AM  It looks like a key Valeant deal might be falling apart, and now the stock is tanking
09:40AM  Uh Oh, Valeant's Hiring. Why That's Very Bad News. at Barrons.com
08:32AM  Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
Nov-29-16 04:03PM  Mallinckrodt Earnings Top, But Stock Dives On Guidance
04:01PM  Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® PR Newswire
04:01PM  Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® CNW Group
11:05AM  What Do Analysts Have to Say about Mallinckrodt?
10:01AM  Valeant: Rooting For a Salix Sale? at Barrons.com
Nov-28-16 06:25PM  Mallinckrodts Greater Dependence on Acthar and Generic Business
Nov-27-16 04:54PM  Why Mallinckrodt Is Trading at a Discount on PE Basis
04:54PM  Behind Mallinckrodts Performance Based on EV-to-EBITDA
Nov-26-16 01:45PM  Smart Money is Pouring Into NetApp Inc. (NTAP) at Insider Monkey
Nov-25-16 08:44PM  Valeant Stock Could Fall 35%: Analyst (VRX) at Investopedia
Nov-24-16 11:02AM  3 Stocks That Have Been Complete Turkeys in 2016 at Motley Fool
Nov-23-16 09:39PM  Bill Miller Likes Buffetts Timing On Airlines, Talks Valeant (VRX)s Free Cash Flow, Amazon (AMZN)s Fate Under Trump at Insider Monkey
03:18PM  Eli Lilly: What Really Ails Big Pharma at The Wall Street Journal
12:10PM  [$$] Four traders exit Paulson & Co's London office at Financial Times
08:47AM  Valeant Pharma downgraded by Mizuho
Nov-22-16 03:27PM  Are These Criminal Charges the Nail in Valeant's Coffin? at Motley Fool
08:59AM  Index-Fund Bans and Hedge-Fund Data at Bloomberg
12:05AM  [$$] Valuation Experts Will Be Held to a New Standard at The Wall Street Journal
Nov-21-16 01:19PM  5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them at Motley Fool
10:43AM  Valeant Stock Attracting More Short Sellers (VRX) at Investopedia
08:12AM  Vetr Thinks Regeneron Is Looking Healthy
08:00AM  Valeant's Asset Sale Clock is Ticking at Bloomberg
01:00AM  Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition PR Newswire
Nov-18-16 02:55PM  Is Valeant Pharmaceuticals the Turnaround Opportunity of a Lifetime? at Motley Fool
12:45PM  Criminal Charges Against Former Valeant Exec 'Not Pertinent But Underscores Cautious Outlook'
11:57AM  Valeant and Philidor After the Criminal Charges
11:22AM  Valeant: The Shorts Are Back in Town at Barrons.com
07:49AM  Valeant Suffers From Too Much Legal Risk: Wells Fargo (VRX) at Investopedia
07:45AM  Does Valeant's Bad News Even Matter Anymore? at Motley Fool
12:23AM  [$$] U.S. Attorney Charges Former Valeant, Philidor Executives, Alleging Fraud and Kickback Scheme at The Wall Street Journal
Nov-17-16 08:22PM  [$$] U.S. Prosecutors Charge Former Valeant, Philidor Executives at The Wall Street Journal
07:27PM  Money in Medicine: The 30 drug and device makers who paid Oregon doctors the most at bizjournals.com
06:10PM  'Charged with a crime for doing his job': VALEANT DUO FIGHTS BACK
04:56PM  Ex-Valeant, Philidor execs arrested for fraud, conspiracy
04:13PM  Valeant's Pharmacy Ties Get Even Murkier at Bloomberg
04:00PM  What we know about the former Valeant employee who just got arrested on fraud charges
04:00PM  STOCKS RISE: Here's what you need to know
03:06PM  Valeant and Philidor Execs Were Building 'Nest Eggs' from Valeant Stakeholders' Money, Bharara Says
02:02PM  Valeant (VRX) 'Ripped Off Pretty Hard' by Own People
01:53PM  [$$] Two executives charged over illegal kickback scheme at Valeant at Financial Times
01:30PM  Fraud Charges for Former Valeant, Philidor Executives
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM